Efficacy of Soberana 02 and Soberana Plus Three-Dose Scheme Achieves 91.2%

Efficacy of Soberana 02 and Soberana Plus three-dose scheme achieves 91.2% Doctor Vicente Vérez Bencomo, director of the Finlay Vaccine Institute (IFV), made the announcement on Thursday. Havana, July 8 (RHC) -- The efficacy of the Soberana 02 vaccine candidate in its three-dose schedule together with Soberana Plus is 91.2%, which exceeds the World Health Organization (WHO) requirements for a vaccine candidate against COVID-19 to become a vaccine, which is 50%. Doctor Vicente Vérez Bencomo, director of the Finlay Vaccine Institute (IFV), made the announcement at this Thursday's meeting of the Government's Temporary Working Group for the prevention and control of COVID-19. This result was established by an Independent Committee, and although the scientific achievement already meets vaccine status, its emergency use will be authorized in due course by the Center for State Control of Medicines, Equipment, and Medical Devices (CECMED). This same vaccination scheme is being tested in Cuban children and adolescents through the Soberana- Pediatrics clinical trial, whose objective is to evaluate the safety, reactogenicity, and immunogenicity of the prophylactic anti-SARS-CoV-2 vaccine candidates. The First Secretary of the Communist Party of Cuba, Miguel Díaz-Canel Bermúdez, congratulated the scientists of the Finlay Vaccine Institute and other institutions that participated in the creation of Soberana, "a result -he said- that shows how hard our scientists have worked." On June 21, it was reported that the Abdala vaccine candidate has an efficacy of 92.28% in its three-dose schedule. The dossier of the Abdala vaccine candidate, with efficacy of 92.28%, has already been submitted by its developer (the Center for Genetic Engineering and Biotechnology) to the Cuban regulatory entity, the Center for State Control of Medicines, Equipment and Medical Devices (CECMED), to obtain the authorization for emergency use. Both results are obtained in a scenario of circulation of the new strains in the country. https://www.radiohc.cu/en/noticias/nacionales/263317-efficacy-of-soberana-02-and-soberana-plus-three- dose-scheme-achieves-912 Radio Habana Cuba.

Copy Link

Recommended publications

Cuba: One Year Into the Pandemic
BULLETIN OF PAHO/WHO IN CUBA Vol. 25 No.1 JANUARY-MARCH 2021 CUBA: ONE YEAR INTO THE PANDEMIC 04 43 46 50 OUR NEWS: NOTEWORTHY: OVER A STORY A CUP OF TO TELL: Interview Benefits with Cuba's of a Cúrcumal onga COFFEE Dr. Ricardo Minister pdroject uring WITH… Pereda González: of Public Health, thep andemic Coordinator of Dr. José Angel Concepción the COVID-19 Clinical Portal Miranda Campa Experts Commission Huergo Pathways to Health is a bulletin prepared by the office of the Pan American Health Organization/World Health Organization EDITORIAL (PAHO/WHO) in Cuba. Its main aim is to share the most important aspects of the On March 11, 2020, the Director-General of the World Health Representation's technical cooperation with Organization (WHO) declared the novel coronavirus a pandemic, the country's Ministry of Public Health which at the time already affected 114 nations. Coincidentally, (MINSAP) and other institutions. that same day, the Pedro Kourí Tropical Medicine Institute (IPK) in Havana confirmed the first COVID-19 cases in Cuba. At the one-year anniversary of the pandemic in Cuba, this issue is dedicated to One year into the pandemic, more than 115 million cases and close to 2.6 million deaths have been reported from the disease systematically review key aspects of the worldwide. About half of both these cases and deaths have been national response over the last months. In registered in the Americas, with results differing according to how particular, it includes an interview with the well the response has been organized, how robust the healthcare Minister of Public Health, Dr.
[Show full text]
Revision Rápida
REVISION RÁPIDA EVALUACIÓN DE LAS CARACTERÍSTICAS DE ALMACENAMIENTO, TRANSPORTE Y DISTRIBUCIÓN DE LAS VACUNAS COVID-19 EN ESTUDIO, Y LAS CARACTERÍSTICAS CLÍNICAS DE LA POBLACIÓN CANDIDATA A VACUNACIÓN Noviembre de 2020 El Instituto de Evaluación Tecnológica en Salud – IETS, es una corporación sin ánimo de lucro, de participación mixta y de carácter privado, con patrimonio propio, creado según lo estipulado en la Ley 1438 de 2011. Su misión es contribuir al desarrollo de mejores políticas públicas y prácticas asistenciales en salud, mediante la producción de información basada en evidencia, a través de la evaluación de tecnologías en salud y guías de práctica clínica, con rigor técnico, independencia y participación. Sus miembros son el Ministerio de Salud y Protección Social – MinSalud, el Departamento Administrativo de Ciencia, Tecnología e Innovación – Colciencias, el Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA, el Instituto Nacional de Salud – INS, la Asociación Colombiana de Facultades de Medicina – ASCOFAME y la Asociación Colombiana de Sociedades Científicas – ACSC. Autores Lucas López Quiceno. Médico y cirujano, Especialista en Epidemiología, Magister en Epidemiología, Magíster en economía de la salud (c). Instituto de Evaluación Tecnológica en Salud - IETS. Jhyld Carolaind Camacho Barbosa, Nutricionista y Dietista, Magister en Epidemiología. Instituto de Evaluación Tecnológica en Salud - IETS. Kelly Estrada-Orozco. Médica, Magister en Epidemiología Clínica, Magister en Neurociencia. Doctorado en Salud Pública (actual). Doctorado en Epidemiología Clínica (actual). Instituto de Evaluación Tecnológica en Salud - IETS. Revisores Cortes-Muñoz, Ani Julieth. Bacterióloga y laboratorista clínica. MSc. Epidemiología. Instituto de Evaluación Tecnológica en salud - IETS. Ospina-Lizarazo, Nathalie. Nutricionista Dietista. MSc. Epidemiología Clínica. Instituto de Evaluación Tecnológica en salud - IETS.
[Show full text]
Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
[Show full text]
COVID-19 Vaccines Update Supplement Week Of: 21Sth June, 2021
CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 21sth June, 2021 I. Overview of Development and Regulatory Approvals: • 102 candidate vaccines are in clinical development: 18 in Phase 3 trials, and 5 in Phase 4 trials – Table 1; Figure in COVID-19 Vaccines and Therapeutics Regulatory Tracker (Phases tab). • 18 vaccines have received regulatory approvals in various countries, and 18 are at various stages of engagement with WHO for emergency use listing (EUL) including vaccines made in Cuba. • 8 vaccines have been approved by WHO for EUL to date: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), Janssen-Cilag, AstraZeneca (Vaxzevria™), Moderna (mRNA-1273), Sinopharm-BIBP and Sinovac COVID-19 vaccine – CoronaVac: Table 4. • COVID-19 vaccine interim recommendations by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) for reviewed vaccines may be found at: SAGE COVID-19 materials. • CARPHA’s COVID-19 vaccine regulatory tracker provides an overview of profiles and regulatory approvals for various candidate vaccines and therapeutics. This sheet includes information on the efficacy of the vaccines in light of current variants of concern, as per WHO updates. • CARPHA-CRS has recommended 7 COVID-19 vaccines to Member States to date – Table 4. The CRS has started its review of Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac. Table 1: Candidate Vaccines under Clinical evaluation, by type or platform. Platform Description Phase
[Show full text]
The Covid–19 Pandemic and Haemglobin Isorders
THE COVID–19 PANDEMIC AND HAEMGLOBIN ISORDERS UPDATE: 29 June 2021 Vaccinations “Immunization is a key component of primary health care and an indisputable human right. It is also one of the best health investments money can buy. Vaccines are thus critical to the prevention and control of infectious-disease outbreaks. They underpin global health security and will be a vital tool in the battle against antimicrobial resistance”. – WHO https://www.who.int/health- topics/vaccines-and- immunization “Since the beginning of the pandemic, WHO has taken steps to prevent an “infodemic”— defined by the organization as “an overabundance of information and the rapid spread of misleading or fabricated news, images, and videos.” WHO and the Wikimedia Foundation, the nonprofit organization that administers Wikipedia, have established a collaboration to expand the public’s access to the latest and most reliable information about COVID-19”. Information about the initiative is available at: https://www.who.int/news/item/22-10- 2020- the-world-health-organization-and-wikimedia-foundation-expand-access-to- trusted- information-aboutcovid-19-on-wikipedia TIF shares the concerns of false information and misleading overabundance of information. This often happens in the effort to enhance hope to a population that is suffering not only from the disease itself, but also from its economic future, since lockdown/isolation practices are stifling the market economies of every country around the world. Hope however, must be based on realistic expectations and information. For these reasons, TIF updates on new developments concerning vaccinations and new therapies are scanned for accuracy and are reviewed now more regularly.
[Show full text]
COVID-19 Vaccine Coverage Soumya Swaminathan, WHO Chief Scientist
COVID-19 vaccine coverage Soumya Swaminathan, WHO Chief Scientist 6 July 2021 DATA AS OF 5 JULY 8:00 AM CET 3,197M doses of COVID-19 vaccine have been administered1 in 215 countries, areas, territories & economies2 Total doses administered per 100 population Doses administered per 100 population 0-5 6-20 21-50 50+ Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 1 1. Source of data: WHO; Bloomberg; 2. Total of 220 countries, areas, territories & economies: 218 economies listed by World Bank + WHO Member states Cook Islands + Niue DATA AS OF 5 JULY 8:00 AM CET COVAX has now shipped 95.9M doses to 135 participants Incl. 69 LMIC/LICs; 40 participants started their first campaigns thanks to COVAX doses COVAX participants that received COVAX doses (incl. ones that started with others) Economies vaccinating only with bilateral doses or donations Economy not yet started vaccinating1 1. Burundi, Eritrea, United Republic of Tanzania, Haiti, Democratic People's Republic of Korea Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
[Show full text]
Status of COVID-19 Vaccines Within WHO EUL/PQ Evaluation Process
Vaccines Guidance Document 07 April 2021 Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process Manufacturer Name of Vaccine NRA of Record Platform EOI Pre-submission Dossier accepted for Status of assessment** Anticipated decision accepted meeting held review* date*** 1. BNT162b2/COMIRNATY EMA Nucleoside modified mNRA Finalized 31/12/20 Tozinameran (INN) 2. AZD1222 Core – EMA Non- Recombinant ChAdOx1 adenoviral Accepted core data of Core data – now as 1st wk April 2021 COVAX vector encoding the Spike protein AZ – non-Covax donation for COVAX. antigen of the SARS-CoV-2. Data for Covax sites Awaited April 2021 onwards EU Nodes expected in April 2021 onwards 3. AZD1222 MFDS KOREA Recombinant ChAdOx1 adenoviral Finalized 15 Feb 2021 SK BIO vector encoding the Spike protein antigen of the SARS-CoV-2. 4. Serum Institute of India Covishield (ChAdOx1_nCoV- DCGI Recombinant ChAdOx1 adenoviral Finalized 15 Feb 2021 19) vector encoding the Spike protein antigen of the SARS-CoV-2. 5. Ad26.COV2.S EMA Recombinant, replication- Core data (US +NL sites) Finalized 12 March 2021 incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Additional sites awaited Awaited To be fixed after data the (SARS-CoV-2) Spike (S) protein submission 6. 1 SARS-CoV-2 Vaccine (Vero NMPA Inactivated, produced in Vero cells In progress End April 2021 Sinopharm / BIBP Cell), Inactivated (lnCoV) 7. SARS-CoV-2 Vaccine (Vero NMPA Inactivated, produced in Vero cells In progress End April 2021 Cell), Inactivated 8. mRNA-1273 EMA mNRA-based vaccine In progress using the Mid. April 2021 encapsulated in lipid nanoparticle abridged procedure (LNP) (EMA).
[Show full text]
March 17, 2021
1996 - 2021 SILVER JUBILEE YEAR TMQ to Marquez expand speeds up return operations ahead of Qatar in Qatar double-header Business | 01 Sport | 12 WEDNESDAY 17 MARCH 2021 4 SHA'ABAN - 1442 VOLUME 26 NUMBER 8564 www.thepeninsula.qa 2 RIYALS QFFD signs $10m contribution Amir visits Milipol Qatar 2021 agreement to support WHO QNA — DOHA that one billion more people benefiting from UHC, one The State of Qatar, repre- billion more people sup- sented by Qatar Fund for ported during emergencies Development (QFFD), and the and one billion more World Health Organization enjoying better health and (WHO) have signed a Core well-being. It also supports Contribution Agreement for the initiatives of speeding $10m to support WHO’s Thir- Core Contribution Agreement is up the access to the teenth General Programme of to support WHO’s Thirteenth essential supplies needed in Work (GPW 13) and for General Programme of Work the fight against COVID-19, COVID-19 response through (GPW 13) and for COVID-19 to include accelerating the the Access to COVID-19 Tools development of COVID-19 Accelerator (ACT-A). response through the Access to tests, treatment and vacci- This is the first Core Con- COVID-19 Tools Accelerator nation while ensuring fair tribution Agreement signed (ACT-A). access.” between the State of Qatar Dr. Hanan Al Kuwari com- and WHO, highlighting the The State of Qatar through mended the pivotal role of strong partnership and com- WHO, especially in the current mitment to work jointly Qatar Fund for Development difficult time as the world is ensuring the most vulnerable (QFFD) is providing its first fighting the coronavirus communities around the flexible funding to WHO in (COVID-19) pandemic.
[Show full text]
“Estamos Trabajando Para La Nueva Normalidad”
K Y M C EN FALLIDO ROBO Distribución en La Plata, Berisso y Ensenada. Precio de tapa: $50 Incendiaron un club a Entrega bajo puerta: $50 metros del destacamento policial de Arturo Seguí Año XXVII • Nº 8866 -PÁG. TRAMA URBANA Edición de 32 páginas En la noticia La Plata, lunes 28 de junio de 2021 15 Boom exportador bonaerense En lo que refiere a ventas al exterior, “Estamos trabajando para la Provincia tuvo este año su cuatrimestre récord en casi una década. El fenómeno es impulsado por el crecimiento de las Diario laHoy dialogó nueva con el presidente de la normalidad”Universidad Nacional de La Plata, Fernando Tauber, quien manufacturas, pero también por otras producciones que atraen a se refirió a la importante labor que desarrollan desde las diferentes áreas para enfrentar la pandemia países como Indonesia e Irán -PÁG. 10 -PÁG. 6 Descubren dos nuevos ejemplares de yaguareté -PÁG. 13 Rápidos y furiosos 9 lidera la taquilla -PÁG. 12 ESPECTÁCULOS FÚTBOL “AMERICANO” Juega la Selección y diario Hoy entrevistó a los campeones Con el fin de agasajar al personal sanitario y agradecerle por su esfuerzo en la pandemia, vecinos de Ringuelet El conjunto de Scaloni enfrentará desde desdeAmor hace tres meses regalan facturasy ensolidaridad las guardias de los nosocomios y en las postas de vacunación las 21 a Bolivia buscando asegurarse la cima del Grupo A. Este multimedio -PÁG. 9 conversó en Brasilia con los integrantes del equipo de fútbol americano que ganaron allí el segundo título consecutivo Los lugares ideales para el cicloturismo en Argentina -PÁG. 15 -PÁGS.
[Show full text]
Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED)
Cuba's Women of Science Cuba’s National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED) Tania L. Aguilar-Guerra MD MS, Esther M. Fajardo-Díaz MS, Conner Gorry MA As of this writing, more than 4.6 million Cubans (over 40% of the population on the island), had received at least their E. Añé fi rst dose of Soberana 02 or Abdala, two of fi ve vaccine candidates for SARS-CoV-2 developed and produced on the island. Late-phase clinical trial data revealed that Abdala is 92.28% effective after the full, three-dose cycle and Soberana 02 is 91.2% effective after two doses, when followed by a booster of Soberana Plus.[1] Cuban health authorities have committed to vaccinating the entire population, including children aged 3–18 years old, using these vaccines by the end of 2021. The fi rst pre-clinical, peer-reviewed data are available,[2] with clinical trial results already submitted to various international journals. Building on decades of biotechnology know-how developing, producing and administering 11 preventive vaccines for childhood diseases—used in the nation’s universal health system and also marketed elsewhere—Cuba is the fi rst, and to date only, country in Latin America and the Caribbean to develop its own vaccine candidates for COVID-19 (Soberana 01; Soberana 02; Soberana Plus; Abdala and Mambisa; see Box on following page). In a strategy designed to ensure comprehensive and importantly, independent solutions to the global health crisis, research institutes and manufacturing hands-on experience in nearly every facet of regulation.
[Show full text]
Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
[Show full text]
Current Scenario of Sars-Coronavirus 2: Epidemiology; Post-Covid-19 and Global Impacts
CURRENT SCENARIO OF SARS-CORONAVIRUS 2: EPIDEMIOLOGY; POST-COVID-19 AND GLOBAL IMPACTS Vishnu Priya Sampatha*, Prasannaraj Govindarajb, Ramasamy Subbiah c, Makesh Mohand Address(es): a State-Key Laboratory for Mechanical Behavior of Materials, School of Material Science & Engineering, Xi'an Jiaotong University, Xi'an 710049, China. b Neurochemistry Laboratory, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India. c Cardiac Hypertrophy Laboratory, Department of Molecular Biology, School of Biological Sciences, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India. d Department of Physics, National Institute of Technology, Karnataka (NITK) Surathkal 575025, Karnataka, India. *Corresponding author: [email protected] https://doi.org/10.15414/jmbfs.4066 ARTICLE INFO ABSTRACT Received 11. 12. 2020 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly contagious strain of coronavirus that causes Coronavirus Disease 2019 (COVID-19) infection, which has distressed the world's health and wealth. This Global Pandemic outbreak has affected Revised 17. 6. 2021 public health enormously at various customs. The investigation of SARS-CoV-2 is still at infancy; however, based on the available Accepted 29. 6. 2021 reports, this review gives an overview of the epidemiology, genomic landscape, diversity of SARS-CoV-2, viral genome pathogenic Published xx.xx.201x interactions, associating factors for COVID-19 infections, post-COVID-19, disease manifestations with their comorbidities, the major obstacles and the preventive measures along with current vaccine strategies of SARS-CoV-2. This review also summarizes all the Regular article relevant evidence of COVID-19 illness, which can provide valuable information on the SARS-CoV-2 genome and its mode of action strategies, thus delivering additional knowledge about COVID-19.
[Show full text]